Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
HIVE (HIVE) 24-hour amplitude reaches 64.8%: Trading volume surges triggering low market cap speculative rally

HIVE (HIVE) 24-hour amplitude reaches 64.8%: Trading volume surges triggering low market cap speculative rally

Bitget PulseBitget Pulse2026/05/05 11:24
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, HIVE price surged from a low of $0.0593 to a high of $0.0977. The current quote is $0.0878, with a volatility amplitude of 64.8%. The 24-hour trading volume has significantly expanded to about $46 million - $81.9 million, a substantial increase compared to usual levels.

Brief Analysis of the Cause of the Movement

- Explosive increase in trading volume: 24-hour transaction volume soared to a high of $81 million, pushing the price to rapidly surge from around $0.059. Community monitoring indicates this as an “explosive breakout” for a low market cap token.

- No clear news or on-chain event: No official announcements, large whale transfers, or project updates have been observed in the past 24 hours. Only signs of market-wide low cap rotation.

Market View and Outlook

Community sentiment is highly optimistic: CoinMarketCap voting shows 84% bullish and CoinGecko 80% bullish. Mainstream opinion claims strong momentum, suggesting buying on pullbacks to the $0.079-$0.083 range, targeting $0.088-$0.100, but warns of the risks of chasing highs and a potential pullback if the $0.0825 support fails.

Note: This analysis is automatically generated by AI based on publicly available data and on-chain monitoring, and is for informational purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million

RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.

智通财经2026/09/21 16:16